Biotech Values

[Assist]

How about FDMT's 4D-150? from Claude:
Phase 3 Program: 4FRONT
4FRONT-1 is a multicenter, randomized, double-masked, Phase 3 trial comparing 4D-150 to aflibercept 2 mg in treatment-naïve wet AMD patients. The primary endpoint is non-inferiority in best-corrected visual acuity (BCVA) change from baseline at 52 weeks. The key secondary endpoint is reduction in treatment burden (number of injections) in the 4D-150 arm versus the control arm. GlobeNewswire
Enrollment for 4FRONT-1 was completed ahead of schedule, exceeding 500 patients randomized. A second identical Phase 3 trial, 4FRONT-2, is enrolling globally (including treatment-experienced patients), with topline data from both trials expected in H2 2027. GlobeNewswire